Italo Tempera

This study shows that NAD metabolism supports CTCF-cohesin chromatin regulation in EBV-transformed B-cells and identifies NAMPT inhibition as a potential therapeutic strategy.

This study identifies CDC7 and POU2F1 as direct targets of EBNA1 in EBV+ epithelial cancers using VK1727 inhibition, revealing new therapeutic strategies.

The paper investigates the effects of decitabine on EBV-associated gastric cancer by integrating transcriptomic and methylome data, revealing retinoic acid pathway activation as a potential therapeutic target.

This study shows lamin A/C maintains genome structure and transcriptional programs needed for EBV-driven B cell activation, with loss causing chromatin reorganization and gene expression changes.

This study shows H2A.Z.1 works with EBNA1 to maintain EBV latency by regulating chromatin structure and gene expression.

This study shows that WAPL suppresses LMP1 and LMP2A expression in EBV latency I by altering DNA looping and histone marks, preventing the transition to latency II.